Expression of Membrane Progesterone Receptors (mPR/PAQR) in Ovarian Cancer Cells: Implications for Progesterone-Induced Signaling Events

Hormones and Cancer

Volumn 1, Issue 4, 2010, Pages 167-176

  Charles, Nathan J ^a   Thomas, Peter ^b   Lange, Carol A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

Apoptosis; cAMP; Jun kinase (JNK); Membrane progesterone receptor (mPR); Ovarian cancer; p38 Mitogen activated protein kinase; PAQR; Progesterone

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADIPONECTIN RECEPTOR; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PROGESTERONE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROTEIN BAX;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROGESTERONE; PROGESTINS; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 78650200109     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0023-9     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Cho KR, Shih Ie M (2009) Ovarian cancer. Annu Rev Pathol 4: 287-313.
3. Leung PC, Choi JH (2007) Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 13: 143-162.
4. Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I et al (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344: 1250-1254.
5. Thomas HV, Murphy MF, Key TJ, Fentiman IS, Allen DS, Kinlen LJ (1998) Pregnancy and menstrual hormone levels in mothers of twins compared to mothers of singletons. Ann Hum Biol 25: 69-75.
6. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Salmeron-Castro J, Hernandez-Avila M (1999) Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 59: 3658-3662.
7. Tambyraja AL, Sengupta F, MacGregor AB, Bartolo DC, Fearon KC (2004) Patterns and clinical outcomes associated with routine intravenous sodium and fluid administration after colorectal resection. World J Surg 28: 1046-1051, discussion 1051-1042.
8. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J et al (1998) Cancer incidence in a cohort of infertile women. Am J Epidemiol 147: 1038-1042.
9. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61: 6768-6776.
10. Gross TP, Schlesselman JJ, Stadel BV, Yu W, Lee NC (1992) The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol 136: 46-53.
11. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL et al (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139: 654-661.
12. Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE (2001) Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 12: 307-312.
13. Greer JB, Modugno F, Allen GO, Ness RB (2005) Short-term oral contraceptive use and the risk of epithelial ovarian cancer. Am J Epidemiol 162: 66-72.
14. Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 371: 303-314.
15. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS et al (1998) Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5: 271-276.
16. Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M et al (2002) Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 94: 50-60.
17. Lee BH, Hecht JL, Pinkus JL, Pinkus GS (2002) WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 117: 745-750.
18. Noguchi T, Kitawaki J, Tamura T, Kim T, Kanno H, Yamamoto T et al (1993) Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J Steroid Biochem Mol Biol 44: 657-660.
19. Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T et al (2002) Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res 93: 807-815.
20. Lau KM, Mok SC, Ho SM (1999) Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96: 5722-5727.
21. Thomas P (2008) Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions. Front Neuroendocrinol 29: 292-312.
22. Zhu Y, Bond J, Thomas P (2003) Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci USA 100: 2237-2242.
23. Zhu Y, Rice CD, Pang Y, Pace M, Thomas P (2003) Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA 100: 2231-2236.
24. Thomas P, Pang Y, Dong J, Groenen P, Kelder J, de Vlieg J et al (2007) Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. Endocrinology 148: 705-718.
25. Karteris E, Zervou S, Pang Y, Dong J, Hillhouse EW, Randeva HS et al (2006) Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol 20: 1519-1534.
26. Tubbs C, Thomas P (2009) Progestin signaling through an olfactory G protein and membrane progestin receptor-alpha in Atlantic croaker sperm: potential role in induction of sperm hypermotility. Endocrinology 150: 473-484.
27. Cai Z, Stocco C (2005) Expression and regulation of progestin membrane receptors in the rat corpus luteum. Endocrinology 146: 5522-5532.
28. Ashley RL, Arreguin-Arevalo JA, Nett TM (2009) Binding characteristics of the ovine membrane progesterone receptor alpha and expression of the receptor during the estrous cycle. Reprod Biol Endocrinol 7: 42.
29. Ashley RL, Clay CM, Farmerie TA, Niswender GD, Nett TM (2006) Cloning and characterization of an ovine intracellular seven transmembrane receptor for progesterone that mediates calcium mobilization. Endocrinology 147: 4151-4159.
30. Romero-Sanchez M, Peiper SC, Evans B, Wang Z, Catasus L, Ribe A et al (2008) Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors. Hum Pathol 39: 1026-1033.
31. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG (2005) Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci 25: 5066-5078.
32. Pierson-Mullany LK, Lange CA (2004) Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol 24: 10542-10557.
33. Dressing GE, Thomas P (2007) Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer. Steroids 72: 111-116.
34. Milligan G (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 158: 5-14.
35. Shaw TJ, Keszthelyi EJ, Tonary AM, Cada M, Vanderhyden BC (2002) Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. Exp Cell Res 273: 95-106.
36. Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2: 599-609.
37. Syed V, Mukherjee K, Lyons-Weiler J, Lau KM, Mashima T, Tsuruo T et al (2005) Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene 24: 1774-1787.
38. Matsukawa J, Matsuzawa A, Takeda K, Ichijo H (2004) The ASK1-MAP kinase cascades in mammalian stress response. J Biochem 136: 261-265.
39. Miller WE, Lefkowitz RJ (2001) Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr Opin Cell Biol 13: 139-145.
40. Arafat WO, Gomez-Navarro J, Xiang J, Barnes MN, Mahasreshti P, Alvarez RD et al (2000) An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer. Mol Ther 1: 545-554.
41. Marone M, Scambia G, Mozzetti S, Ferrandina G, Iacovella S, De Pasqua A et al (1998) bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res 4: 517-524.
42. Wu GS (2004) The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3: 156-161.
43. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D et al (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562.
44. Fister S, Gunthert AR, Aicher B, Paulini KW, Emons G, Grundker C (2009) GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res 69: 6473-6481.
45. Kim BJ, Ryu SW, Song BJ (2006) JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 281: 21256-21265.
46. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y et al (2003) Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256.
47. Lee LF, Li G, Templeton DJ, Ting JP (1998) Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273: 28253-28260.
48. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Trope CG et al (2003) Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 91: 160-172.
49. Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR et al (1997) Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79: 1944-1950.
50. Syed V, Ho SM (2003) Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 22: 6883-6890.
51. Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM (2007) Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 102: 442-452.
52. Chao KC, Wang PH, Yen MS, Chang CC, Chi CW (2005) Role of estrogen and progesterone in the survival of ovarian tumors-a study of the human ovarian adenocarcinoma cell line OC-117-VGH. J Chin Med Assoc 68: 360-367.
53. Belinson JL, McClure M, Badger G (1987) Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol 28: 151-155.
54. Chen X, Feng Y (2003) Effect of progesterone combined with chemotherapy on epithelial ovarian cancer. Chin Med J (Engl) 116: 388-391.